STUDY OF EFFECTIVENESS AND SIDE EFFECTS OF FAVIPIRAVIR THERAPY ON MILD AND MODERATE COVID-19 PATIENTS

Didik Hasmono; Alfa Frista Arta; Ismawati; Ruddy Hartono; Mohammad Subhan

doi:10.24252/kesehatan.v15i2.29380

Didik Hasmono Universitas Airlangga
(ID)
Alfa Frista Arta Clinical Pharmacy Student, Faculty of Pharmacy, Universitas Airlangga
(ID)
Ismawati Pharmacy Student, Faculty of Pharmacy, Universitas Airlangga
(ID)
Ruddy Hartono Clinical Pharmacist in Bhayangkara H.S. Samsoeri Mertojoso Hospital
(ID)
Mohammad Subhan Pulmonologist in Bhayangkara H.S. Samsoeri Mertojoso Hospital
(ID)

DOI: https://doi.org/10.24252/kesehatan.v15i2.29380

Keywords: Favipiravir, COVID-19, Effectiveness and Side Effects

Abstract

Introduction: Corona Virus Disease-2019 (COVID-19) is divided into five degrees that are asymptomatic, mild, moderate, severe and critical. Recently, Favipiravir known as off-label antivirals for COVID-19 that inhibits RNA-dependent RNA polymerase (RdRp) and is administered orally 2x1600 mg as loading dose and 2x600 mg as a maintenance dose. Methods: This observational retrospective study aims to determine effectiveness (PCR/Rapid Ag, temperature, respiratory rate, oxygen saturation, and chest X-ray) and side effects (digestive, uric acid, liver, blood, glucose, and lipids profile) of Favipiravir in mild and moderate COVID-19; which inclusion criteria were Favipiravir (5-10 days); a group of antibacterials: Azithromycin (therapy A), Levofloxacin (therapy B), and combination (therapy C); vitamins, minerals, symptomatic and comorbid therapy; and Fondaparinux used in moderate degree then described quantitatively. Results: This study obtained 47 HMR dominated by males (55%), aged 19-30 years (36%), cough symptoms (72,3%), and no comorbid status (70.2%). Favipiravir (6-7 days) is effective for mild and moderate degree in all effectiveness parameters with average length in mild degree was 6-12 days and moderate degree was 8-13 days. Possible interaction with Paracetamol was found. Most side effects were diarrhea and no significant side effects were found on liver profile (AST and ALT), glucose profile, and blood profile (leukocytes and erythrocytes). Conclusions: This result suggests that increasing collaboration of pharmacists with other healthcare in monitoring the use of Favipiravir related to interactions, uric acid, and lipid profiles, also effects in patients under 18 years, men, and elderly is important.

Downloads

Download data is not yet available.

References

Badan pengawas Obat dan Makanan, B. (2021). Keputusan Kepala Badan Pengawas Obat dan Makanan RI No. HK.02.02.1.2.03.20.134 Tahun 2020 Tentang Penetapan Pedoman Obat dalam Penangan Corona Virus Disease (COVID-19). 2019.

Badan Pengawas Obat dan Makanan, B. (2020). Fact Sheet For Health Care Providers Emergency Use Authorization (EUA) Offavipiravir For Treatment of COVID-19 Patients.

Cai, H. (2020). Sex difference and smoking predisposition in patients with COVID-19. January, 19–20. https://doi.org/10.1111/all.14238.Yang

Chen, C., Zhang, Y., Huang, J., Yin, P., Cheng, Z., Wu, J., Chen, S., Zhang, Y., Chen, B., Lu, M., Luo, Y., Ju, L., Wang, X., Technology, E., & Hospital, W. L. (2020). Favipiravir versus Arbidol for COVID-19 : A Randomized Clinical Author affiliations :

Clinical Practice Book Preparation. (2020). Clinical Practice Guideline for Corona Virus Disease 2019 (COVID-19) RSUD Dr. Soetomo Edition 1.

Ivashchenko, A. A., Dmitriev, K. A., Vostokova, N. V, Azarova, V. N., Kravchenko, D. V, Lomakin, N. V, Merkulova, E. A., & Natalia, A. (2020). AVIFAVIR for Treatment of Patients with Moderate COVID-19 : Interim Results of a Phase II / III Multicenter Randomized Clinical Trial. 1–8.

James. (2020). Preliminary Report of the Favipiravir Observational Study in Japan.

KEMENKES, K. kesehatan. (2020). Pedoman Pencegahan dan Pengendalian Corona Virus Disease-2019 (COVID-19) Revisi ke-5. Kementrian Kesehatan Republik Indonesia, 8(1), 1–214. https://doi.org/10.29239/j.agrikan.8.1.-

Murai, Y., Kawasuji, H., Takegoshi, Y., Kaneda, M., & Kimoto, K. (2021). International Journal of Infectious Diseases Case Report A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test. International Journal of Infectious Diseases, 106, 33–35. https://doi.org/10.1016/j.ijid.2021.03.048

Perhimpunan Dokter Paru Indonesia, P. (2020). Diagnosis dan Penatalaksanaan Pneumonia COVID-19 di Indonesia.

Poschet, J. F., & Perkett, E. A. (2020). Azithromycin and ciprofloxacin have a chloroquine-like effect on respiratory epithelial cells. 1–21.

Scroggs, S. L. P., Offerdahl, D. K., Flather, D. P., Morris, C. N., Kendall, B. L., Broeckel, R. M., Beare, P. A., & Bloom, M. E. (2021). against SARS-CoV-2 and MERS-CoV. 1–12.

Shannon, A., Selisko, B., Le, N. T. T., Huchting, J., Touret, F., Piorkowski, G., & Fattorini, V. (2020). Favipiravir strikes the SARS-CoV-2 at its Achilles heel , the RNA polymerase. 1–19.

Shrestha, D. B., Budhathoki, P., Khadka, S., & Shah, P. B. (2020). Favipiravir versus other antiviral or standard of care for COVID ‑ 19 treatment : a rapid systematic review and meta ‑ analysis. Virology Journal, 1–15. https://doi.org/10.1186/s12985-020-01412-z

Toyama, C. (2014). Review report : favipiravir (avigantablet 200 mg). Pharmaceu. and Med. Dev.Agency, 31–112.

World Health Organization. (2020). Table of therapeutics in WHO A coordinated Global Research Roadmap. World Health Organization, February, 6-7 February 2018, Geneva, Switzerland. http://www.who.int/emergencies/diseases/2018prioritization-report.pdf?ua=1

Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020). Angiotensin ‑ converting enzyme 2 ( ACE2 ) as a SARS ‑ CoV ‑ 2 receptor : molecular mechanisms and potential therapeutic target. Intensive Care Medicine, 46(4), 586–590. https://doi.org/10.1007/s00134-020-05985-9